HONG KONG – It is not surprising that Tokyo-based Kyowa Hakko Kirin Co. Ltd. wants to hold on to Nesp (darbepoetin alfa), an erythropoiesis-stimulating agent used as a treatment for improving renal anemia, when the patent expires in 2019.